World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2025

D-Index & Metrics

Immunology

D-Index
140
Citations
64984
World Ranking
165
National Ranking
110

Medicine

D-Index
141
Citations
70756
World Ranking
1634
National Ranking
951

Research.com Recognitions

  • 2025 - Research.com Immunology in United States Leader Award

Overview

David M. Goldenberg is affiliated with Immunomedics in the United States and has a substantial publication record in the field of Medicine, with a particular focus on Oncology. Their research spans several subfields including Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Surgery, and Epidemiology.

The scientist's work addresses key topics such as:

  • HER2/EGFR in Cancer Research
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Treatment and Pharmacology
  • Advanced Breast Cancer Therapies
  • LGBTQ Health, Identity, and Policy
  • Tracheal and airway disorders
  • Colorectal Cancer Treatments and Studies

David M. Goldenberg has contributed to multiple publications in prominent venues, including:

  • Annals of Oncology
  • Cancer Research
  • Oncotarget
  • npj Breast Cancer
  • Journal of Nuclear Medicine

The scientist has collaborated frequently with several co-authors, such as Robert T. Sataloff, Robert M. Sharkey, Edward Fisher, Ehab Y. Hanna, and Jonas T. Johnson.

Selected recent papers authored or co-authored by David M. Goldenberg include:

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial, 2021, Annals of Oncology
  • Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial, 2020, Annals of Oncology
  • Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy, 2020, Expert Opinion on Biological Therapy

Best Publications

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

    D.M. Goldenberg;F. DeLand;E. Kim;S. Bennett

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

    David M. Goldenberg;Thomas M. Cardillo;Serengulam V. Govindan;Edmund A. Rossi

  • Ionization−Reactivity Relationships for Cysteine Thiols in Polypeptides†

    Grzegorz Bulaj;Tanja Kortemme;David P. Goldenberg

  • CYSTIC LYMPH NODE METASTASIS IN PATIENTS WITH HEAD AND NECK CANCER: AN HPV-ASSOCIATED PHENOMENON

    David Goldenberg;Shahnaz Begum;William H. Westra;Zubair Khan

  • Immunotherapy of B-cell malignancies using anti-CD22 antibodies

    David M. Goldenberg

  • A Novel Method of 18F Radiolabeling for PET

    William J. McBride;Robert M. Sharkey;Habibe Karacay;Christopher A. D'Souza

  • Targeted Therapy of Cancer with Radiolabeled Antibodies

    David M Goldenberg

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Oral complications of radiotherapy.

    James J Sciubba;David Goldenberg

  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy

    David M. Goldenberg;Robert M. Sharkey;Giovanni Paganelli;Jacques Barbet

  • Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen

    D M Goldenberg;E E Kim;F H DeLand;S Bennett

  • First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

    Alexander N. Starodub;Allyson J. Ocean;Manish A. Shah;Michael J. Guarino

  • Kinetic role of a meta-stable native-like two-disulphide species in the folding transition of bovine pancreatic trypsin inhibitor☆

    T.E. Creighton;D.P. Goldenberg

  • Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

    Edmund A. Rossi;David M. Goldenberg;Thomas M. Cardillo;William J. McBride

  • Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

    Thomas Dörner;Joerg Kaufmann;William A Wegener;Nick Teoh

  • Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

    Thomas M. Behr;David M. Goldenberg;Wolfgang Becker

  • Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

    Thomas M. Cardillo;Serengulam V. Govindan;Robert M. Sharkey;Preeti Trisal

  • Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

    Rosalyn D Blumenthal;Evelyn Leon;Hans J Hansen;David M Goldenberg

  • Tracheotomy Complications: A Retrospective Study of 1130 Cases:

    David Goldenberg;Eliav Gov Ari;Avishay Golz;Joshua Danino

  • Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

Frequent Co-Authors

Robert M. Sharkey
Robert M. Sharkey University of Fukui
Chien-Hsing Chang
Chien-Hsing Chang Northwestern University
Hans J. Hansen
Hans J. Hansen Eisai (Japan)
Edmund A. Rossi
Edmund A. Rossi Immunomedics (United States)
Gary L. Griffiths
Gary L. Griffiths National Institutes of Health
Otto C. Boerman
Otto C. Boerman Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Ivan D. Horak
Ivan D. Horak Freie Universität Berlin
Jacques Barbet
Jacques Barbet University of Nantes
Aditya Bardia
Aditya Bardia Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare and nursing pathways. For those interested in expanding their qualifications quickly, exploring accelerated np programs can be a strategic move. These programs offer an efficient route for nurses aiming to become Nurse Practitioners, allowing them to deepen their clinical expertise and impact in immunology-related fields.

If you don’t have a nursing background but wish to enter this domain, consider enrolling in online bsn programs for non nurses. These programs help non-nurses acquire foundational nursing knowledge, which is crucial for immunology research and patient care roles.

For quicker entry into nursing alongside immunology interests, candidates often look for accelerated nursing programs near me. These are designed to fast-track your education, enabling a faster transition into the workforce.

Additionally, accredited lpn programs easy to get into provide foundational nursing credentials and serve as a stepping stone for further specialization relevant to immunology careers.

Best Scientists Citing David M. Goldenberg

Trending Scientists

Recently Published Articles